Nanomédicaments pour le traitement de maladies graves et recherches duales
The use of nanotechnologies for the encapsulation of pharmacologically active molecules (nanomedicines) has enhanced the delivery of these molecules within the body after administration. By releasing the active ingredient at the level of pathological cells and tissues, these nanocarriers help reduce...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Académie des sciences
2024-11-01
|
| Series: | Comptes Rendus Biologies |
| Subjects: | |
| Online Access: | https://comptes-rendus.academie-sciences.fr/biologies/articles/10.5802/crbiol.168/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206287072231424 |
|---|---|
| author | Couvreur, Patrick |
| author_facet | Couvreur, Patrick |
| author_sort | Couvreur, Patrick |
| collection | DOAJ |
| description | The use of nanotechnologies for the encapsulation of pharmacologically active molecules (nanomedicines) has enhanced the delivery of these molecules within the body after administration. By releasing the active ingredient at the level of pathological cells and tissues, these nanocarriers help reduce toxicity while improving therapeutic efficacy. They also protect fragile molecules from rapid metabolization and can promote their intracellular penetration. Nanomedicines have made significant advances in various therapeutic areas such as oncology, infectious diseases, and several neurological disorders. They have also contributed to groundbreaking discoveries, including the introduction of the first mRNA vaccine (against COVID-19), and have improved certain imaging and diagnostic techniques, too. Depending on the country and therapeutic indications, between 40 to 60 nanomedicines are currently on the market, with over a hundred in clinical trials. This review aims to describe and discuss the characteristics and functionalities of the different generations of nanocarriers, from their inception to the present day, discussing the prospects they offer for the production of therapeutic proteins, for facilitating gene editing (CRISPR/Cas9), and for enabling immune checkpoint blockade in oncology. The potential of extracellular vesicles and exosomes as drug carriers is also explored. These advances compel researchers to consider the dual risks, both conscious and unconscious, that they may pose. |
| format | Article |
| id | doaj-art-1b8750dbe4594b05a6afe65196020884 |
| institution | Kabale University |
| issn | 1768-3238 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Académie des sciences |
| record_format | Article |
| series | Comptes Rendus Biologies |
| spelling | doaj-art-1b8750dbe4594b05a6afe651960208842025-02-07T10:37:47ZengAcadémie des sciencesComptes Rendus Biologies1768-32382024-11-01347G118719810.5802/crbiol.16810.5802/crbiol.168Nanomédicaments pour le traitement de maladies graves et recherches dualesCouvreur, Patrick0https://orcid.org/0000-0001-7961-5443Académie des Sciences, Paris, France; Institut Galien Paris Saclay, UMR CNRS 8612, Université Paris-Saclay, Orsay Cedex, FranceThe use of nanotechnologies for the encapsulation of pharmacologically active molecules (nanomedicines) has enhanced the delivery of these molecules within the body after administration. By releasing the active ingredient at the level of pathological cells and tissues, these nanocarriers help reduce toxicity while improving therapeutic efficacy. They also protect fragile molecules from rapid metabolization and can promote their intracellular penetration. Nanomedicines have made significant advances in various therapeutic areas such as oncology, infectious diseases, and several neurological disorders. They have also contributed to groundbreaking discoveries, including the introduction of the first mRNA vaccine (against COVID-19), and have improved certain imaging and diagnostic techniques, too. Depending on the country and therapeutic indications, between 40 to 60 nanomedicines are currently on the market, with over a hundred in clinical trials. This review aims to describe and discuss the characteristics and functionalities of the different generations of nanocarriers, from their inception to the present day, discussing the prospects they offer for the production of therapeutic proteins, for facilitating gene editing (CRISPR/Cas9), and for enabling immune checkpoint blockade in oncology. The potential of extracellular vesicles and exosomes as drug carriers is also explored. These advances compel researchers to consider the dual risks, both conscious and unconscious, that they may pose.https://comptes-rendus.academie-sciences.fr/biologies/articles/10.5802/crbiol.168/NanomédicamentsNanovecteursDrug deliveryOncologieThérapeutiques de précisionVectorisationNanotoxicologie |
| spellingShingle | Couvreur, Patrick Nanomédicaments pour le traitement de maladies graves et recherches duales Comptes Rendus Biologies Nanomédicaments Nanovecteurs Drug delivery Oncologie Thérapeutiques de précision Vectorisation Nanotoxicologie |
| title | Nanomédicaments pour le traitement de maladies graves et recherches duales |
| title_full | Nanomédicaments pour le traitement de maladies graves et recherches duales |
| title_fullStr | Nanomédicaments pour le traitement de maladies graves et recherches duales |
| title_full_unstemmed | Nanomédicaments pour le traitement de maladies graves et recherches duales |
| title_short | Nanomédicaments pour le traitement de maladies graves et recherches duales |
| title_sort | nanomedicaments pour le traitement de maladies graves et recherches duales |
| topic | Nanomédicaments Nanovecteurs Drug delivery Oncologie Thérapeutiques de précision Vectorisation Nanotoxicologie |
| url | https://comptes-rendus.academie-sciences.fr/biologies/articles/10.5802/crbiol.168/ |
| work_keys_str_mv | AT couvreurpatrick nanomedicamentspourletraitementdemaladiesgravesetrecherchesduales |